

CORRECTION

Correction: Taraxasterol inhibits cell proliferation and angiogenesis in ovarian cancer by targeting EphA2

Chunhui Wang^{1,*}, Suwei Lan¹, Bing Han¹, Xingcha Wang¹

¹Department of Gynecology, Affiliated Hospital of Chengde Medical University, 067000 Chengde, Hebei, China

***Correspondence**

chunhui1233@163.com (Chunhui Wang)

The authors wish to issue the following correction to the published article [1]:

Three citations in the Introduction and Discussion sections were not optimally matched to the supported statements. These have been replaced with more appropriate and directly relevant references. These changes do not affect the results, their interpretation, or the overall conclusions of the study.

Revised References:

The corrected references are as follows:

[6] Kim JH, Kim SI, Park EY, Ha HI, Kim JW, Coleman RL, *et al.* Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: a systematic review and meta-analysis. *Gynecologic Oncology*. 2023; 179: 24–32.

[7] Kongkamsuan W, Boonyapipat S. Epithelial ovarian cancer in younger age versus older age groups: survival and

clinicopathological features. *Journal of Cancer Research and Therapeutics*. 2024; 20: 363–368.

[22] Li S, Yang M, Zhao R, Peng L, Liu W, Jiang X, *et al.* Defective EMC1 drives abnormal retinal angiogenesis via Wnt/ β -catenin signaling and may be associated with the pathogenesis of familial exudative vitreoretinopathy. *Genes & Diseases*. 2023; 10: 2572–2585.

The authors sincerely apologize for any inconvenience or confusion caused by the previous citations and confirm that this correction does not affect the scientific conclusions or overall findings of the study.

REFERENCES

- [1] Wang CH, Lan SW, Han B, Wang XC. Taraxasterol inhibits cell proliferation and angiogenesis in ovarian cancer by targeting EphA2. *European Journal of Gynaecological Oncology*. 2024; 45: 62–67.